The p53 protein has appropriately been named the “guardian of the genome”. In almost all human cancers, the powerful tumor suppressor function of p53 is compromised by a variety of mechanisms, including mutations with either loss of function or gain of function and inhibition by its negative regulators MDM2 and/or MDMX. We review herein the progress made on different therapeutic strategies for targeting p53.
CITATION STYLE
Aguilar, A., & Wang, S. (2023, January 1). Therapeutic Strategies to Activate p53. Pharmaceuticals. MDPI. https://doi.org/10.3390/ph16010024
Mendeley helps you to discover research relevant for your work.